




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/569, 33/68, A61K 39/21 C12P 21/08	A1	(11) International Publication Number: WO 92/15885 (43) International Publication Date: 17 September 1992 (17.09.92)
(21) International Application Number: PCT/US92/01749 (22) International Filing Date: 6 March 1992 (06.03.92) (30) Priority data: 668,266 11 March 1991 (11.03.91) US (71) Applicant: IDEC PHARMACEUTICALS CORPORATION [US/US]; 11099 North Torrey Pines Road, Suite 160, La Jolla, CA 92037 (US). (72) Inventor: KANG, Chang-Yuil ; 1736 Buttercup Road, Encinitas, CA 92024 (US). (74) Agents: DAHL, Nancy, K. et al.; Lyon & Lyon, 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US).		(81) Designated States: AT (European patent), AU, BE (European patent), BR, CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>

(54) Title: METHODS FOR SELECTING ANTIBODY REAGENTS; ANTI-IDIOTYPE ANTIBODIES; AND AIDS VACCINE FORMULATIONS

**(57) Abstract**

A panel of monoclonal anti-idiotype antibodies

A novel method is disclosed for selecting antibody reagents for vaccine formulations that are capable of inducing group-neutralizing anti-HIV antibody responses in humans. Also disclosed are anti-idiotype antibodies and hybridoma cell lines capable of producing such antibodies. Further, anti-idiotype antibody-based vaccines and formulations thereof are disclosed. The methods, antibodies, hybridomas and vaccine formulations of the present invention may be useful in the treatment and prevention of HIV infection.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

DESCRIPTION

Methods for Selecting Antibody Reagents;
Anti-Idiotypic Antibodies; and
AIDS Vaccine Formulations

Field of the Invention

The present invention relates generally to the field of immunology and, more particularly, to novel methods of selecting for therapeutically useful antibodies. Further,
5 the present invention relates to novel anti-idiotypic antibodies and vaccine formulations thereof that are useful in the immunotherapy and prevention of HIV infection.

Background of the Invention

It is widely accepted that the Human Immunodeficiency
10 Virus (HIV) is the principal etiological agent of the acquired immunodeficiency syndrome (AIDS). From a clinical standpoint, depletion of CD4⁺ lymphocytes can account for most of the severe immunologic abnormalities in AIDS patients (Fauci, et al. (1984) *Am. Int. Med.* 100:92). The
15 tropism of HIV is dependent primarily upon a specific interaction between the gp120 envelope glycoprotein of HIV and the CD4 receptor molecule on target cells, e.g., T lymphocytes and macrophages, although it has been suggested that other molecules on some cells are involved in
20 similar interactions with HIV. Beyond the primary interaction between CD4 and gp120, the following steps are postulated to be essential for HIV entry into target cells: anchorage of the virus to the cell membrane; fusion with the cell membrane; and penetration of the
25 viral elements into the cell. Any reagent that interferes with these steps is considered to block the virus infection and is of potential therapeutic value. Such reagents under current investigation include antibodies, which are generally functionally described as "neutralizing
30 antibodies."

SUBSTITUTE SHEET

Amino acid sequence analysis of various HIV isolates from a single patient as well as different patients indicates that gp120 contains hypervariable regions interspersed among highly conserved regions. This finding indicates that HIV variation *in vivo* can occur rapidly during the chronic infection. The degree of diversity among different strains of HIV within the gp120 molecule may be due in part to natural selection during interactions with the host immune system. Antibodies that bind to hypervariable regions of the HIV envelope generally only react with a single isolate or strain of the virus: such antibodies are termed "type-specific." At present, about 20 different strains of HIV have been identified. For example, antibodies directed against one of these hypervariable regions of gp120 known as the "V3 loop" will neutralize HIV. However, this effect has generally been type-specific; i.e., it is well documented that among anti-gp120 antibodies, those specific to the V3 loop may exert a neutralizing effect on only a single isolate or strain of HIV. Moreover, a single amino acid mutation in the V3 region allows the virus to escape neutralization by such antibodies. Although the precise role of the V3 domain in virus infection is still in question, several reports have demonstrated that antibodies to this region neutralize virus infectivity by interfering with a post-binding event (Skinner, et al. (1988) *J. Virol.* 62:4194). Whatever the V3 region's role may be in virus infection, its variability from strain to strain and high mutation frequency make it an uncertain target for immunotherapy.

Despite the considerable sequence variation and hypervariability within gp120, all known HIV isolates share a common functional characteristic--the ability to bind to and infect CD4⁺ cells. This observation leads to a basic premise that the CD4 attachment site on gp120 includes one or more conserved domains. Accordingly, antibodies binding to this CD4 attachment site could be expected to prevent viral infections and to interact fully

with various HIV isolates via their ability to bind to conserved regions of gp120. Antibodies that bind to conserved regions of HIV and recognize multiple strains of the virus are termed "group-specific." Thus, antibodies that will neutralize multiple strains of HIV are said to be capable of group-specific neutralization. These neutralizing antibodies would play an important role in preventing viral infection (Weiss, et al. (1985) *Nature* 316:69) as well as killing HIV-infected cells via antibody-dependent cell-mediated cytotoxicity (Rook, et al. (1987) *J. Immunol.* 138:1064) and complement-mediated cytotoxicity. It has been well documented that antibodies specific to the conserved region exist in the sera of HIV-infected humans (Schmittman, et al. (1988) *J. Immunol.* 141:4181; Moore, J.P. (1990) *AIDS* 4:297). Therefore, an HIV vaccine which induces antibodies capable of group-specific neutralization may be effective in producing a clinical improvement in AIDS patients and preventing infection in healthy people.

Although the clinical correlation between neutralizing antibody titer and disease progression has not been well defined, recent reports suggest that the presence of maternal antibodies to gp120 correlates positively with the uninfected status of children born to seropositive mothers (Rossi, et al. (1989) *Proc. Natl. Acad. Sci.* 86:8055; Devash, et al. (1990) *Proc. Natl. Acad. Sci.* 87:3445). However, as most HIV-seropositive individuals have a high titer of anti-HIV antibodies as well as demonstrable levels of neutralizing antibodies, it remains unresolved as to why so many of these people have a rapidly progressive infection. In attempting to answer this question, Applicant has noted in the literature that high titers of type-specific neutralizing antibody in HIV-infected individuals are not sufficient to neutralize continuously emerging new isolates brought about by mutations of gp120 (Nara, et al. (1990) *In Vaccines* 90:137, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

SUBSTITUTE SHEET

On the other hand, titers of group-specific neutralizing antibodies in HIV-infected individuals, which are specific against conserved regions, are low. It is, therefore, Applicant's premise that HIV vaccines must be evaluated with respect to their ability to induce high titers of group-specific neutralizing antibodies.

Although the need for a HIV vaccine is clear and the objective rationally conceived, the vaccine strategies adopted have been diverse and, to date, unsuccessful. Most HIV vaccine development strategies have been based on preparations including whole or portions of the major envelope protein. Native, recombinant, synthetic, vaccinia-encoded envelope proteins and whole inactivated virus have been prepared and tested.

For example, chimpanzees were immunized with the HIV envelope protein encoded in a vaccinia virus. The animals produced both humoral (antibody) and cellular (T-cell) immune responses specific for the envelope protein; however, these primates were not protected from infectious challenge with HIV (Hu, et al. (1989) *Nature* 328:721).

Kennedy and colleagues, using synthetic peptides which represent conserved immunodominant epitopes of gp41, immunized chimpanzees with a peptide carrier conjugate made from the synthetic peptides (Kennedy, et al. (1989) *In Vaccines* 250, Cold Spring Harbor, NY). Subsequent challenge with HIV, however, showed that the animals were not protected against infection. The use of killed whole virus vaccine (Salk, J. (1987) *Nature* 327:473) may be able to induce protection, but to the extent these vaccines contain envelope, this protection is expected to be only type-specific and does not circumvent the problem with the envelope polymorphism (Hahn, et al. (1986) *Science* 23:1548).

According to a recent report (Berman, et al. (1990) *Nature* 345:622), immunization of primates with recombinant gp120, induced neutralizing antibodies and elicited

protective immunity against homologous strains of HIV. Still, there was no evidence that such immunization could provide protective immunity against different HIV strains or even mutated homologous isolates.

5 Antibody based vaccine approaches have also been investigated. For example, the use of anti-idiotypic antibodies ("anti-ids") as vaccines against various infectious agents ("antigens") (so-called idiotypic vaccines) is well documented. To date, most idiotypic vaccine develop-
10 ment strategies have been based on the following preparations and principles. First, to generate monoclonal anti-ids (Ab2s), animal Ab1s (in most cases antibodies from non-human sources have been used) have been utilized as immunogens or templates. Second, monoclonal Ab1s have
15 been used as templates in the majority of cases. Third, the in vitro selection of Ab2s as vaccine candidates was driven by the concept of antigen mimicry by anti-ids (Ab2s); i.e., the principle of blocking the interaction of Ab1 with Ab2 by antigen has been used as the controlling
20 criteria for selecting Ab2 vaccine candidates. Such anti-idiotypic antibodies have become known in the art as "Ab2 β " or "internal image" Ab2s. Two other types of Ab2s generated against Ab1s have been designated: Ab2 λ , which block antigen binding to Ab1, but are not internal images
25 of the antigen; and Ab2 α , which bind to the Ab1, but do not block binding of the antigen to Ab1. See FIGURE 1. Fourth, to further define Ab2s as vaccine candidates in vivo, non-primate animals have generally been used as animal models to evaluate the Ab3 response.

30 Despite the tremendous financial and human resources that have been dedicated to the discovery of an effective AIDS vaccine, the results have been inconclusive at best. The reasons for these apparent failures are unclear, but some of these studies indicate that broadly reactive anti-
35 HIV neutralizing antibodies were not generated in sufficient titer in the experimental animals, allowing HIV to "escape" the immune response.

SUBSTITUTE SHEET

Summary of the Invention

The present invention is based on Applicant's discovery of a novel method for selecting antibody reagents for vaccine formulations that are capable of inducing group-neutralizing anti-HIV antibody responses in humans.

In its broadest embodiment, the present invention is directed to a method of selecting monoclonal anti-idiotypic antibody reagents useful in vaccine formulations for the treatment or prevention of HIV infection. The first step in this method requires preparing human polyclonal anti-gp120 antibodies (Ab1s) and subsequently generating a first group of monoclonal anti-idiotypic antibodies (G1-Ab2s) capable of reacting with or immunologically binding with the human polyclonal anti-gp120 antibodies. Then, from this first group of monoclonal anti-idiotypic antibodies (G1-Ab2s), a second group or subset of monoclonal anti-idiotypic antibodies (G2-Ab2s) are selected that are characterized by their ability to immunologically bind gp120 antibodies that neutralize *in vitro* multiple strains of HIV. Finally, the second group of monoclonal anti-idiotypic antibodies (G2-Ab2s) is screened for a subset or a third group of monoclonal anti-idiotypic antibodies (G3-Ab2s) which are characterized by their ability to generate an anti-anti-idiotypic antibody (Ab3) response in a primate host, wherein the anti-anti-idiotypic antibody (Ab3) immunologically binds with gp120 and neutralizes *in vitro* multiple strains of HIV.

In a preferred embodiment of the invention, the Ab1s are prepared from pooled human sera from HIV-positive asymptomatic individuals and purified by passing over a gp120 column to increase the concentration of anti-gp120 antibodies. Also preferred is the generation of murine monoclonal Ab2s.

The present invention is further directed broadly to monoclonal anti-idiotypic antibodies that are capable of eliciting a group neutralizing anti-HIV antibody response in humans. The present invention is also directed to

monoclonal anti-idiotyp antibodies (G3-Ab2s) selected according to the methods described herein.

The present invention is further directed to vaccine formulations including the monoclonal anti-idiotyp antibodies (G3-Ab2s) disclosed herein.

Thus, it is an object of the present invention to develop a method for selecting antibody reagents useful in vaccine formulations which are capable of eliciting *in vivo* high titers of group-specific neutralizing antibodies against HIV in humans.

It is a further object of the present invention to develop antibody reagents *per se* that are useful in vaccine formulations and the cell lines capable of producing such antibodies.

Brief Description of the Drawings

FIGURE 1 graphically illustrates the concepts of "idiotyp matching" (1A) and "idiotyp mimicry" (1B).

FIGURE 2 shows that the flowthrough fraction of Total Anti-gp120 Abs bound to gp120_{IIIB} and not to gp120_{SF2}.

FIGURE 3 shows that the Total Anti-gp120 Abs bound to gp120_{IIIB} and not to gp120_{SF2}.

FIGURE 4 graphically depicts the purification of Total Anti-gp120 Abs.

FIGURE 5 illustrates the effective inhibition of ¹²⁵I-labeled gp120_{SF2}/ CD4 by CD4-site antibodies.

FIGURE 6 depicts HIV virus neutralizing activity of CD4-site antibodies.

FIGURE 7 depicts HIV virus neutralizing activity of non-V3 antibodies.

FIGURE 8 lists the first group of anti-idiotyp antibodies and the characteristics of corresponding Ab1s.

FIGURE 9 summarizes the characterization of corresponding Ab3s against candidate Ab2 vaccines in monkeys.

FIGURE 10 summarizes the neutralizing activity of Ab3 isolated from 3C9 immunized monkeys.

FIGURE 11 depicts neutralizing activity of human 3C9+Ab against HIV laboratory strains (Left) and patient primary HIV isolates (Right).

FIGURE 12 depicts the binding of gp120_{SF2} (Left) and
5 gp120_{IIIIS} (Right) to purified Ab3 from monkeys PRO703 and PRO783.

Detailed Description of the Preferred Embodiments

The present invention is based on Applicant's novel anti-idiotypic (anti-id or Ab2) approach to developing an
10 HIV vaccine that possesses the critical biological property of eliciting group-specific neutralizing antibodies. Although the Applicant does not wish to be bound by any particular theory, the present invention is driven by the concept of "idiotype matching" rather than the prior art
15 concept of "antigen mimicry" by anti-ids.

"Idiotypic matching" utilizes anti-ids as surrogates for antigen, e.g., in an attempt to stimulate specific elements of the B cell repertoire in humans. In contrast to the prior art, which focus exclusively on idiotype
20 mimicry and Ab2B, the anti-id vaccine candidates of the present invention may be Ab2 A, B, or λ as long as they elicit group neutralizing Ab3 responses. Compare, FIGURE 1A and FIGURE 1B.

In short, most prior art anti-idiotypic vaccine
25 development strategies have been based upon antigen mimicry and the resulting principles:

(1) To generate monoclonal anti-ids, non-human Ab1s have been utilized as templates.

(2) Monoclonal Ab1s have been used as templates in
30 the majority of cases.

(3) The in vitro assays used to select Ab2s as vaccine candidates have generally been based on the concept of antigen mimicry by anti-ids (Ab2B).

(4) To further define Ab2s as vaccine candidates in
35 vivo, non-primates have been the animal model of choice.

Notwithstanding the scientific momentum created by these teachings in the art, Applicant developed an entirely new approach for the selection of anti-id vaccines. Some of the preferred features and advantages of Applicant's invention include the following:

(1) Human Ab1s, preferably purified from seropositive healthy individuals, are used as templates to generate Ab2s. This choice of starting material increases the likelihood that the Ab2-based vaccine will generate Ab3s in humans that are immunologically equivalent to the human Ab1s with respect to antigen binding potential, i.e., anti-HIV binding. This feature of the invention takes advantage of the fact that Applicant knows that B cell repertoires pre-exists in humans that are capable of producing Ab1-like Ab3s (so called Ab1'). In contrast, using a murine Ab1 assumes that the B cell repertoire of the mouse is genetically and immunologically equivalent to the human B cell repertoire--possibly a fatal flaw for vaccine development.

(2) Polyclonal Ab1s rather than monoclonal Ab1s are used as templates to generate Ab2s. This feature of the invention eliminates the possibility that an individual monoclonal Ab1 (which represents only one epitope) selected for use as a template does not represent a highly conserved HIV epitope.

(3) Applicant has discovered that the definition of Ab2 B and the evaluation of Ab3 responses in non-primate animals are not the critical factors in selection of an Ab2 as a vaccine candidate. In contrast, Applicant has discerned the following criteria for the selection of anti-idiotypic vaccines: (a) Ab1s (which react with the Ab2 vaccine candidate) from the human sera exhibit desirable biological effects *in vitro* (e.g., virus neutralization). Ergo, Ab3s generated *in vivo* in primates, including humans, in response to an Ab2 vaccine are expected to have Ab1-like biological effects. (b) Ab2s induce group-specific neutralizing Ab3s in primates.

The principal advantages in using Applicant's anti-id approach to select an HIV vaccine are threefold. First, selected anti-ids elicit only beneficial anti-gp120 antibodies (e.g., group-specific neutralizing antibodies).
5 Second, anti-ids elicit high titers of certain anti-gp120 antibodies. Third, the biological properties of anti-gp120 antibodies elicited by these Ab2 are predictable.

Thus, in its broadest embodiment, the present invention is directed to a method of selecting monoclonal
10 anti-idiotypic antibody reagents that are useful in vaccine formulations for the treatment and prevention of HIV infection. The first step in this method involves the preparation of human polyclonal anti-gp120 antibodies (Ab1s) that are to be used as templates to generate Ab2s.
15 It is preferred that the human polyclonal anti-gp120 antibodies are obtained from human sera of HIV-positive, asymptomatic individuals. It is further preferred that such sera is purified to increase the representation of anti-gp120 antibodies by passing the pooled human sera
20 over a gp120 column. It is also contemplated by the present invention that the total anti-gp120 antibodies will be passed over not one but two gp120 columns, wherein each gp120 column represents a different strain of gp120. It is most preferred that the human polyclonal anti-gp120
25 antibodies represent the total anti-gp120 antibodies. Alternatively, the total anti-gp120 antibody population can be dissected into fractions for use in the present invention: CD4 attachment site-specific anti-gp120 antibodies, V3 region-specific anti-gp120 antibodies or
30 non-V3 region-specific anti-gp120 antibodies.

The second step of the method of the present invention involves the generation of a first group of monoclonal anti-idiotypic antibodies which are capable of reacting with the human polyclonal anti-gp120 antibodies
35 prepared in the first step of the method. Preferably, these anti-idiotypic antibodies are murine monoclonal antibodies generated by conventional hybridoma technology.

As used herein, the term "monoclonal" is intended to encompass antibodies derived from a single clone as well as mono-specific antibodies derived by molecular biology techniques. Alternative sources of anti-idiotypic antibodies contemplated by the present invention include human, primate, chimeric, and humanized antibodies, as well as antibodies synthesized by molecular biology techniques. As used herein, the term "antibody" is intended to include whole antibodies, antibody fragments, Fab fragments, single chain antibodies, and immunologically functional antibody equivalents.

Once the first group of monoclonal anti-idiotypic antibodies have been generated, the third step in the method of the present invention involves screening this first group of antibodies for a second group (subset of first group) of monoclonal anti-idiotypic antibodies that are characterized by their ability to react with or immunologically bind anti-gp120 antibodies that neutralize *in vitro* multiple strains of HIV. In a preferred embodiment, the anti-gp120 HIV neutralizing antibodies are human. In a most preferred embodiment, these human anti-gp120 HIV neutralizing antibodies are human antibodies selected from the pool of human polyclonal antibodies prepared according to the first step of the method. As used herein, neutralization of more than two strains of HIV is considered to be "multiple" strain neutralizing. These anti-gp120 antibodies may be selected by passing the human polyclonal antibody preparation made in the first step of the method over an Ab2 (group 1) column, and selecting those anti-gp120 antibodies that are capable of *in vitro* neutralization of multiple strains of HIV.

The present invention is also directed to antibodies, in particular, to monoclonal anti-idiotypic antibodies that are capable of eliciting a group-neutralizing anti-HIV antibody response in humans. Preferred are monoclonal anti-idiotypic antibodies selected according to the selection method described above.

Hybridoma cell lines are also an aspect of the present invention. In particular, hybridoma cell lines capable of producing a monoclonal anti-idiotypic antibody that is capable of eliciting a group neutralizing anti-HIV antibody response in humans. The most preferred is the hybridoma cell line deposited with the ATCC, Rockville, MD on March 8, 1991, designated accession no. HB10701. In addition to the antibodies produced by this hybridoma, the present invention includes monoclonal antibodies capable of eliciting a substantially equivalent immune response in humans as a monoclonal antibody produced by the hybridoma cell lines described above. Preferably, such a monoclonal antibody would react with and compete for binding to the same anti-gp120 antibody as a monoclonal antibody produced by the hybridoma cell lines described above.

An additional embodiment of the invention is the development of vaccine formulations including, in mixture with a pharmaceutically acceptable carrier, a monoclonal anti-idiotypic antibody that is capable of eliciting a group neutralizing anti-HIV antibody response in humans. Vaccine formulation, including selection of appropriate adjuvants and carriers, is well known to those of skill in the art. Once formulated, a vaccine's dosimetry would be based upon patient and clinical factors that are well appreciated by those of skill in the art of vaccine delivery. The vaccines of the present invention may be either prophylactic or therapeutic in nature. Although a single anti-idiotypic antibody reagent vaccine is desirable, it is contemplated by the present invention that multiple anti-idiotypic antibodies may be formulated in a "cocktail" vaccine approach. Again, clinical factors will dictate the vaccine formulation and dosage. However, a preferred vaccine formulation would include about 2.5 mg of an antibody of the present invention formulated with about 100 ug of termutide and SAF (Syntex adjuvant formulation -- 2.0 mg polysorbate 80, 12.5 mg Poloxamer 401, and 50 mg

squalane). An alternative formulation may exclude the termutide component.

EXAMPLE 1A Preparation of Starting Materials--Human Polyclonal Total Anti-gp120 Antibodies.

5 Total anti-gp120 antibodies (anti-gp120_{SF2}) ("Total Anti-gp120 Abs") were purified from human sera by affinity chromatography using a gp120_{SF2}-Sephacrose column. Recombinant gp120_{SF2} was derived from engineered CHO cells. A pool of sera from HIV-infected asymptomatic individuals
10 (purchased from North American Biologicals, Inc., Miami, Florida 33169) were inactivated by detergent (1% NP40) and heat (1 hr. at 56°C) treatment. The sera was dialyzed against PBS and ammonium sulfate (40% as final concentration) was added to the sera to isolate the immunoglobulin
15 fraction. The precipitated immunoglobulin fraction was reconstituted with PBS, filtered and applied to the gp120_{SF2}-Sephacrose column. The bound Total Anti-gp120 Abs on the column were eluted with pH 3.0 glycine buffer and dialyzed against PBS. The recovery of total anti-gp120
20 antibodies in sera was approximately 300 µg/ml.

Antibodies binding to gp120_{SF2} are expected to consist of two kinds: (a) _{SF2} type-specific antibodies, and (b) antibodies binding to conserved regions of gp120 such as the CD4-attachment site. Since the individuals contributing to the Ig pool might have been infected with a variety
25 of HIV strains, the flowthrough fraction may bind to gp120 derived from strains other than _{SF2}. Indeed, as shown in FIGURE 2, Applicant found that the flowthrough fraction bound to gp120_{IIIB}, not to gp120_{SF2}, indicating the presence
30 of _{IIIB} type-specific anti-gp120 antibodies in the flowthrough fraction. In addition, Total Anti-gp120 Abs bound to both gp120_{SF2} and gp120_{IIIB} (FIGURE 3), indicating the presence of a mixture of type-specific and cross-reactive anti-gp120 antibodies.

35 Applicant then investigated the neutralizing activities of Total Anti-gp120 Abs against various HIV isolates.

14

FIGURE 2 shows that Total Anti-gp120 Abs exhibited neutralizing activities against four different HIV isolates, although their neutralizing activities against the different HIV isolates varied as much as 10-50 fold, indicating that Total Anti-gp120 Abs contains significantly different populations and amounts of type- and group-specific neutralizing antibodies. From these results, Applicant reasoned that the difference in the neutralizing activities of Total Anti-gp120 Abs against the various viral isolates could be explained by (a) strain-to-strain differences in the amount of anti-gp120 antibodies required for neutralization of each virion, and (b) the presence of type- or group-specific neutralizing antibodies.

To demonstrate the presence of type-specific neutralizing antibodies in Total Anti-gp120 Abs, Applicant tested the binding of Total Anti-gp120 Abs to type-specific neutralizing epitopes derived from the V3 region of different gp120s.

Table 1
Binding Activities of Different Anti-gp120 Antibody Preparations To Peptides Derived From the V3 Region of Various gp120s

Anti-gp120 Antibodies	Binding Activities*				
	Origin of Peptides				
	MN	IIIB	RF	SC	WMJ-2
Total Anti-gp120 Abs	>3	1.05	0.06	0.8	1.48
CD4-site Abs	0.15	0.01	0.01	0.03	0.01

*Binding activities are expressed by O.D. obtained at 5µg/ml of each preparation.

SUBSTITUTE SHEET

Table 1 shows that Total Anti-gp120 Abs bind extensively to the MN isolate derived epitope, less extensively to the IIIB, SC and WMJ-2 derived epitopes and weakly to the RF-derived epitope. Thus, the highest binding activities of Total Anti-gp120 Abs against the MN-derived epitope is consistent with the fact that Total Anti-gp120 Abs exhibited the highest neutralizing activities against the MN isolate. However, it is interesting to note that the binding activity of Total Anti-gp120 Abs to the RF-derived epitope was only slightly above background, despite the fact that Total Anti-gp120 Abs effectively neutralized the RF isolate. This could be explained by the presence of group-specific neutralizing antibodies specific against non-V3 epitopes.

EXAMPLE 1B Preparation of CD4 Site Attachment Site-Specific Polyclonal Anti-gp120 Antibodies from Human Sera

Isolation and Characterization of CD4 Attachment Site-Specific Anti-gp120 Antibodies

Since Applicant observed group-specific neutralizing activities with Total Anti-gp120 Abs, it was of interest to determine the epitope specificity of anti-gp120 antibodies which are responsible for these group-specific neutralizing activities. Since antibodies to the conserved CD4 attachment site of gp120 are considered to be the major group-specific neutralizing epitope, Applicant devised the following strategy. The approach to isolate CD4 attachment site-specific anti-gp120 antibodies (CD4-site Abs) from Total Anti-gp120 Abs consisted of saturating the CD4-attachment site on gp120 immunoabsorbent with sCD4 and followed by applying Total Anti-gp120 Abs to the immunoabsorbent in the presence of excess sCD4. The flowthrough fraction of the antibodies were collected and applied to a protein G column to isolate the IgG fraction from sCD4. This is graphically depicted in FIGURE 4. To ensure complete removal of the sCD4 from the IgG fraction,

Applicant analyzed this preparation by SDS gel electrophoresis and ELISA, using a monoclonal anti-CD4 antibody, and could not detect any sCD4 by either method.

To isolate the CD4 attachment site-specific anti-gp120 antibodies, 10 mg of sCD4 in PBS was repeatedly loaded on the gp120_{SF2}-Sepharose column to saturate the CD4 attachment site onto the gp120. Then, 4 mg of Total Anti-gp120 Abs with 10 mg of sCD4 in PBS was loaded onto the column. The flowthrough fraction was further separated on a protein G column (Pharmacia Fine Chemicals, Piscataway, NJ) to isolate the IgG fraction. SDS gel electrophoresis and ELISA, using a monoclonal anti-CD4 antibody, were employed to verify that the isolated IgG was free of sCD4.

To examine whether the IgG fraction contains CD4-site Abs, Applicant performed competitive inhibition assays on CD4⁺ cells using ¹²⁵I-labeled gp120_{SF2} and CD4-site Abs. FIGURE 5 shows that CD4-site Abs effectively inhibited binding of ¹²⁵I-labeled gp120_{SF2} to CD4 cells. The approximate IC₅₀ of CD4-site Abs in this assay was ten times less than that of sCD4. Applicant observed almost the same results with ¹²⁵I-labeled gp120III_B. This result indicated that this IgG fraction contained significant amounts of CD4-site Abs. To determine what proportion of this IgG fraction are CD4-site Abs, various anti-gp120 antibodies were coated on microtiter plates and incubated with ¹²⁵I-labeled gp120_{SF2} in the presence or absence of sCD4.

Table 2Proportion of CD4 Attachment Site-Specific Antibodies in
Different Anti-gp120 Antibody Preparations

	Anti-gp120	Proportion*
5	Antibodies	as %
	Total Anti-gp120 Abs	16
	CD4-site Abs	71
	Non-V3 Abs	32
	V3-Region Abs	0

10 *The percent inhibition by sCD4 in each anti-gp120 antibody binding to gp120 was calculated. The largest percent inhibition was considered to be the proportion of CD4 attachment site-specific anti-gp120 antibodies.

Table 2 shows that sCD4 inhibited the binding of CD4-site Abs to gp120_{SF2} by 71%, whereas only 16% of Total Anti-gp120 Abs binding to gp120_{SF2} was inhibited by sCD4. This result indicated that our purification significantly enriched CD4-attachment site-specific anti-gp120 antibodies; however, these antibodies still contained substantial amounts of non-CD4 attachment site-specific anti-gp120 antibodies. In an attempt to determine the specificities of the contaminating antibodies in CD4 site Abs, Applicant tested the binding of CD4 site Abs to synthetic peptides derived from the V3 domain of different HIV isolate gp120s. Table 1 shows that CD4 site Abs bound only weakly to the MN isolate-derived epitope and not to the other isolate-derived epitopes. This finding demonstrates that the purification for CD4-site Abs removes most of the V3 region-specific anti-gp120 antibodies.

30 Since Applicant found that CD4-site Abs contain mainly CD4-attachment site-specific anti-gp120 antibodies with minimal amounts of MN isolate specific neutralizing antibodies, Applicant investigated whether CD4-site Abs could neutralize different HIV isolates. As shown in FIGURE 6, CD4-site Abs exhibited almost the same extent of neutralizing activities against three different HIV isolates. Compared with CD4 site Abs, Total Anti-gp120

Abs exhibit much higher neutralizing activities against the MN isolate, a little higher against the RF isolate and almost the same against the III_B isolate. From the fact that CD4 site Abs effectively neutralized three different HIV isolates at or near equivalent antibody concentrations despite low or no binding activities against identical V3 specific peptides, Applicant concluded that CD4-site Abs exhibit mainly non-V3 group-specific neutralizing activities, whereas, Total Anti-gp120 Abs exhibit type- and group-specific neutralizing activities. Applicant utilized these CD4-site Abs to generate murine monoclonal anti-ids.

EXAMPLE 1C. Preparation of Anti-gp120 Antibodies Depleted of Type-Specific Neutralizing Antibodies

Another approach for identifying group-specific neutralizing antibodies was to deplete type-specific neutralizing antibodies from TAGA, using a column of V3 peptide Affi-Gel 401 and test this preparation for group-specific neutralizing activities.

To separate the anti-gp120 antibodies depleted of V3 region-specific antibodies (non-V3 Abs) from Total Anti-gp120 Abs, a mixture of two peptides (8 mg of each) derived from the V3 region of gp120_{SF2} (see peptides for sequence) were coupled to 10 ml of Affi-Gel 401 (Bio-Rad, Richmond, CA). See method below. The peptides were synthesized on an automated peptide synthesizer (model 430A, Applied Biosystems, Foster City, CA) by solid phase method. The peptides were deprotected and cleaved from the support with HF/anisole or the "low-high" HF procedure. The sequences of two SF2-derived peptides for an affinity column were as follows; V3SF2: TRPNNNTRKSIYIGPGRAFHTTGRI IGDIRKAHC and CTRPNNNTRKSIYIGPGRAFHTTGRIIGDIRKAHC. The sequences of various V3 region peptides for binding assays were as follows; MN: YNKRKRIHIGPGRAFYTTKNIIG, IIIB: NNTRKSIRIQRGPGRAFVTIGKIG, RF: NNTRKSITKGPRVIYATGQIIG,

SC: NNTTRSIHIGPGRAFYATGDIIG, WMJ-2:
NNVRRSLSIGPGRAFRTREGN. Ten mg of Total Anti-gp120 Abs in
PBS was repeatedly loaded on the peptide Affi-Gel column.
The flowthrough, consisting of anti-gp120 antibodies
5 depleted of V3 region-specific antibodies (non-V3 Abs),
was collected. SF2 V3 region-specific anti-gp120 anti-
bodies (V3-region Abs) were eluted with pH3 glycine
buffer.

Peptide Coupling

10 1. Derivatization of the Affinity Support

An aliquot of Affi-Gel 401 affinity support was
reduced with 100 mM dithiothreitol for 1 hour at room
temperature. The resin was then transferred to a sintered
glass funnel and washed extensively with argon-saturated
15 phosphate buffered saline.

The reduced resin was then transferred to a 15 ml
conical tube and diluted with 10 ml of argon-saturated
phosphate buffered saline. The bis-maleimidomethyl ether
in ethanol was added to the resin in a 100 fold molar
20 excess of maleimide over sulfhydryls. The reaction was
allowed to proceed overnight at 1-8°C with rotation in a
sealed tube. The resin was subsequently transferred to
a sintered glass funnel and washed extensively with argon-
saturated PBS in order to remove excess reagent.

25 Unreacted sulfhydryls were blocked by the addition of
n-ethylmaleimide in ethanol in a sealed tube with rotation
at 2-8°C overnight.

2. Reduction of Peptide and Coupling to the Derivatized Support

30 Reduction of the C terminal cysteine was effected by
the addition of 100 mM DDT with incubation for 2 hours at
room temperature. The reduced peptide was separated from
r ductant by adsorption to a Sep-Pak C-18 apparatus,
washed with argon-saturated PBS, and eluted directly into
35 the support in solution with 95% CH₃CN. Coupling was

allowed to take place overnight at 2-8°C with rotation in a sealed tube. Following the coupling, the resin was washed with PBS in order to remove excess peptide.

Both bound and flowthrough fractions were tested in virus neutralization assays. FIGURE 7 shows that non-V3 Abs exhibited almost the same extent of neutralizing activities against three different HIV isolates. However, V3 region Abs exhibited strong neutralization activities against the MN isolate, minimal activities against III_B and no activity against RF. Based on these observations, Applicant concluded that the neutralizing activities of non-V3 Abs are group-specific while the neutralizing activities of V3 region Abs are type-specific. This result indicates that the majority of neutralizing activity of Total Anti-gp120 Abs to III_B and RF isolates (FIGURES 7a, 7b) are derived from group-specific neutralizing activities of the non-V3 Abs fraction, whereas, most of the neutralizing activity of Total Anti-gp120 Abs to the MN isolates (FIGURE 7c) are derived from type-specific neutralizing antibodies in the V3 region Abs fraction. Furthermore, by comparison of neutralizing activities of V3 region Abs and non-V3 Abs on MN isolate (FIGURE 7c), Applicant concluded that V3 region Abs are more effective than non-V3 Abs neutralizing antibodies in neutralizing a specific isolate.

Conclusions on Preparation of Anti-gp120 Antibodies in Examples 1A, 1B, and 1A

Applicant has dissected the neutralizing activities of various polyclonal anti-gp120 antibodies present in a pool of serum from 4 HIV-infected individuals to understand the role of these antibodies in the host defense against HIV infection. The major findings of this study are as follows: (i) Total Anti-gp120 Abs exert type- and group-specific neutralizing activities; (ii) the group-specific neutralizing activity is found primarily in CD4-site Abs; (iii) if other group-specific neutralizing

antibodies rather than CD4- site Abs exist, they are not specific against a simple linear epitope of the V3 domain; (iv) V3 region Abs are more effective than non- V3 Abs in neutralizing a specific HIV isolate.

- 5 Although neutralizing efficacy of CD4-site Abs is relatively low, it is reasonable to assume that an HIV vaccine which induces high titers of CD4 site Abs should be effective in producing a clinical improvement in AIDS patients and preventing infection against various HIV
10 isolates in healthy people.

EXAMPLE 2A Generation of First Group of Anti-id Mabs and Characterization for their Ability to React with Human Polyclonal Anti-gp120 Antibodies.

- Generation of anti-id Mabs was accomplished by fusing
15 sp2 murine myeloma cells with splenocytes from mice which were immunized 2-3 times with polyclonal anti-gp120 antibodies. In screening assays, anti-id was selected for (i) binding to polyclonal human anti-gp120 antibodies, (ii) not binding to any specific isotype standard antibody,
20 (iii) no binding to Ig preparation of the same pool of sera depleted of Total Anti-gp120 Abs by absorption on a gp120_{SF2}-Sepharose column.

Immunizations

- BALB/c mice were immunized with TAGA and the various
25 other fractions of polyclonal anti-gp120 antibodies purified from a pool of four sera from HIV-infected individuals as described in EXAMPLES 1A-C. All immunizations were done by two S.C. injections of 50 micrograms of antibody in SAF-MDP adjuvant at two week intervals, followed
30 by a single i.p. injection of 50 micrograms of antibody in incomplete Freund's adjuvant ("IFA") 3 days prior to fusion. Spleen cells were fused with SP2 myeloma cells and hybrids were selected in HAT medium. Culture supernatant were tested by ELISA. Positive clones were

subcloned twice. Anti-id Mabs were purified from the ascites on Protein A-Sepharose columns.

ELISA Assay for Hybridoma Screening

For hybridoma screening assays, microtiter wells were coated with 300 ng of the following human Igs in PBS: Different anti-gp120 antibodies used for immunizations; Ig preparations of the same pool of sera depleted of Total Anti-gp120 Abs by absorption on a gp120_{SF2}-Sepharose column; and myeloma proteins representing all different isotypes of human heavy and light chains (The Binding Site, San Diego, CA). Culture supernatants were tested for their binding activities to the antibody coated plates. Alkaline phosphatase-coupled goat anti-mouse Ig and phosphatase substrate (Sigma, St. Louis, MO) were used to detect antibodies binding to coated plates.

EXAMPLE 3A. Selection of a Second Group of Anti-IDS from the First Group of Anti-IDS Based on in vitro Characterization

Characterization of anti-id Mabs was necessary to identify appropriate antibodies for the next level of experiments. For this procedure, a unique approach to define Ab2s as vaccine candidates in vitro was employed. The underlying principals are based on "idiotype matching" rather than the antigenic mimicry of anti-id (Ab2B). Therefore, the isolation of the corresponding Ab1s to individual Ab2s from human sera and their evaluation was a crucial step. Thus, Applicant isolated the corresponding Ab1s using an Ab2-Sepharose column and tested the Ab1s for binding activity to gp120 and neutralizing activity against multiple strains of HIV. Then, Ab2s which interact with group-specific neutralizing Ab1s were selected for primate studies. See FIGURE 8.

Preparation of Id+Abs (AbIs)

Anti-id Mabs w r conjugated to Sepharose 4B by mixing 8 mg of antibodies with 5 ml of CNBr-activated Sepharose 4B (Pharmacia, Piscataway, NJ). Then, 20-60 ml of the same sera pool used for various anti-gp120 antibody preparation was loaded to anti-id Mab-Sepharose 4B columns. After washing extensively, bound antibodies (Ab1 Ids) were eluted with citrate buffer pH 2.8 and dialyzed against PBS.

10 ELISA

An ELISA plate was coated overnight with 0.2 ml of 0.5 µg/ml of gp120_{SF2} or gp120III_B (SmithKline Beecham, King of Prussia, PA) in 0.1 M bicarbonate buffer pH 9.8. The plate was washed three times with PBS and blocked for 1 hr. with 10% FCS in PBS. After washing, various concentrations of AbIs were added. Two hours later, the plate was washed and biotin-coupled goat anti-human Ig and avidin-coupled peroxidase was used for detecting antibody binding to the ELISA plate.

20 Neutralization assay

A quantitative neutralization assay of HIV by anti-gp120 antibody was conducted as previously described (Nara, et al. (1988) Nature 332:469). The virus stocks of HIV isolates were grown in H9 cells and harvested for optimal viral infectivity and aliquoted and frozen at -140°C in a vapor phase cryo unit. Equivalent amounts of virus (syncytial-forming unit) were used in the assays so as to allow for comparison of the various antibody fraction tested. The assays are repeatable over a virus surviving fraction range of 1 to 0.001 within a two to four fold dilution of the antibody ($p \leq 0.001$).

EXAMPLE 4A. Selection of Third Group of Anti-IDS from the
Second Group Based on AB3 Response in Primates

Demonstrations of HIV Vaccine Activity of Anti-Id Mabs

To identify anti-id Mabs with potential utility in
5 eliciting group-specific neutralizing anti-gp120 anti-
bodies, cynomolgus monkeys were used. Monkeys were
immunized with anti-id Mab/Syntex Adjuvant Formulation
("SAF") (Syntex Corp., Palo Alto, CA) emulsion, each given
at two week intervals. After the fourth immunization,
10 blood samples were taken and sera were isolated and used
to prepare Ab3 preparation on Ab2 affinity column.
Applicant next examined whether Ab3 binds to gp120.

Ab3 binding to gp120

To test gp120 binding activity of Ab3, gp120_{SP2} and
15 gp120_{III_B} were iodinated by Bolton-Hunter reagent (ICN
Biochemical, Cleveland, OH) and lactoperoxidase (Bio-Rad,
Richmond, CA) respectively. Microtiter plates were coated
for 18 hours with 1µg of Ab3 in PBS. After washing, the
plates were blocked for one hour with 1% BSA in PBS,
20 10,000 cpm of gp120_{SP2} or gp120_{III_B} were added to wells and
incubated for 3 hours. After washing three times, each
well was counted.

HIV Neutralization

For neutralizing assays, Ab3 was further purified on
25 gp120-Sepharose affinity column to enrich gp120 specific
Ab3s. Applicant then tested whether gp120 specific Ab3s
neutralize multiple strains of HIV.

Two quantitative neutralization assays of HIV were
performed, as previously described (Nara, et al. (1988)
30 Nature 332:469). Briefly, target cells of the CEM-SS cell
line were infected in monolayers by different HIV isolates
grown in H9 cells, in the presence of Ab3s. After 7-12
days in culture, syncytia forming units were counted, and
supernatants were assayed in ELISA for p24 concentration.

As shown in FIGURES 9 and 10, Applicant found that Ab3s isolated from the sera of 3C9 immunized monkeys bind to gp120 and the purified gp120-specific Ab3s neutralize three distinctive HIV isolates.

5 EXAMPLE 4B. Characterization of 3C9 as Active Immunotherapy Reagent
Immunizations

Four Cynomolgus monkeys received intramuscular injections with 2.5 mg of 3C9 in 1 ml of SAF (Syntex
10 adjuvant formulation) containing 0.6 mg of N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP). The injections were administered bi-weekly. Animals were bled before the injection series and seven days after each injection.

15 Recombinant Proteins

gp120_{IIIB} is a recombinant glycoprotein of an HIV_{IIIB} isolate which is secreted from a *Drosophila* cell line. gp120_{SF2} is a recombinant envelope glycoprotein of an HIV_{SF2} isolate which is secreted from Chinese hamster ovary
20 (CHO) cells. The gp120_{IIIB} and gp120_{SF2} are readily available to those of skill in the art. Recombinant soluble CD4 (sCD4) was prepared by transfection of a truncated CD4 gene into CHO cells. Secreted sCD4 in culture supernatants of CHO cells (representing 95% of the
25 amino-terminal extracellular portion of the molecule) was purified on an anti-CD4 antibody conjugated Sepharose column.

Affinity Purification of Antibodies

All affinity columns were prepared by conjugating 8
30 mg of protein with 5 ml of CNBr-activated Sepharose 4B (Pharmacia). To purify the 3C9-reactive antibody (3C9+Ab) from pooled sera of healthy HIV-infected individuals (Kang, et al. (1991) *Proc. Natl. Acad. Sci. USA* 88, 6171-6175), heat (56°C, 1hr)- and detergent (1% Nonidet P-40)-

treated sera were applied to a 3C9-conjugated Sepharose affinity column. After being washed extensively, bound antibodies (3C9+Abs) were eluted with citrate buffer (pH 2.8) and dialyzed against phosphate-buffered saline (PBS).

5 To purify various Ab3s from monkey sera, all 3C9 immune sera were initially diluted 1:1 with PBS. The diluted serum was then passed over an affinity column of normal mouse immunoglobulin-conjugated Sepharose. The flow-through fraction was collected and set aside. After

10 washing, the bound antibody (anti-isotype Ab) was washed, eluted with citrate buffer, and dialyzed against PBS. Subsequently, the Ab3 was passed over a gp120_{SF2}-Sepharose affinity column, and the column was washed extensively. The bound antibody (gp120-specific Ab3) was eluted with

15 citrate buffer and dialyzed against PBS.

RIA

gp120_{SF2} and gp120_{IIIB} were labeled with ¹²⁵I by using a Bolton-Hunter Reagent Kit (NEN). RIA plates (Dynatech) were coated for 18 hr with various amounts of antibody in

20 PBS. The plates were washed and then blocked for one hr with PBS containing 1% bovine serum albumin (BSA). ¹²⁵I-labeled gp120_{IIIB} or gp120_{SF2} in PRS containing 10% (vol/vol) fetal calf serum and 0.05% Tween 20 was added in the presence or absence of different concentrations of

25 inhibitors. After 3 hr, the plates were washed with PBS and the bound radioactivity was determined in a gamma counter.

ELISA

To test the binding activity of 3C9+Abs to a V3

30 region-derived peptide (amino acids 301-338 of gp120_{SF2}), microtiter plates were coated overnight with 0.25 ug of protein in PBS per well. After the adherent layer was blocked and washed, different concentrations of antibody in PBS were added to the plates. Alkaline phosphatase-

35 coupled goat anti-human immunoglobulin and phosphatase

substrat (Sigma) were us d to d tect antibodies binding to th plates.

Neutralization Assays

Two quantitative neutralization assays with HIV-1
5 laboratory stains were performed, as previously described
(Nara & Fischinger, (1988) Nature (London) 332, 469-470:
Whalley et al. (1992) Viral Immunol., 4, 201-213).
Briefly, monolayers of CEM-SS target cells were cultured
with different HIV strains, in the absence or presence of
10 different neutralizing antibodies. After 3-5 days in
culture, syncytia-forming units were counted and in the
same assay, supernatants were assayed in ELISA for p24
concentration 7-12 days later. Neutralization assays with
HIV primary isolates were performed as described (Daar et
15 al. (1990) Proc. Natl. Acad. Sci. USA 87, 6574-6578).

Property of Anti-Idiotypic mAb 3C9 as Candidate for Clonotypic Stimulation

Using the methods described above, Applicant
generated a series of anti-idiotypic antibodies against
20 purified human anti-gp120 antibodies from a pool of four
healthy HIV-1 infected donors. Briefly, anti-gp120
antibodies were purified on gp120_{SF2} Sepharose and used to
immunize mice for hybridoma fusion. Anti-idiotypic mAbs
were selected for binding to human anti-gp120 antibodies.
25 One anti-idiotypic mAb, 3C9, with specificity for CD4
site-directed anti-gp120 antibodies, was further
characterized as a candidate for induction of anti-gp120
antibodies. Pooled human HIV-1+ sera were purified on a
3C9 immunoabsorbent and eluted antibodies (3C9+Ab) were
30 tested for binding to gp120 and V3 loop peptides. The
results (Table 3), show that 3C9+Ab bound to two
genetically distinct gp120s derived from HIV_{SF2} and HIV₁₁₁₈
and did not bind to the V3 loop peptide. Furthermore,
3C9+Ab binding to gp120 was inhibited by sCD4, indicating
35 that 3C9+Ab is specific for an epitope around the CD4

attachment site of gp120. Next, the biological function of 3C9+Ab was examined in virus neutralization assays. Human 3C9+Ab exhibited different spectra of broadly neutralizing activities against genetically distinct HIV laboratory strains and four primary isolates established from HIV-infected individuals. See Fig. 11. Collectively, these results indicate that anti-idiotypic mAb 3C9 recognizes a clonotypic determinant shared by human polyclonal anti-gp120 antibodies that are specific for a conserved epitope around the CD4 attachment site and exhibit broadly neutralizing activities. By this definition, 3C9 defines a marker on B cells producing neutralizing anti-gp120 antibodies.

Tabl 3.
Immunol gical Prop rti s of Human 3C9-Reactive
Antibodies (3C9+ Ab)

	<u>Binding activity of 3C9+ Ab in assays</u>				
	<u>cpm in RIA with ¹²⁵I-gp120†</u>				
	<u>gp120_{SF2}</u>		<u>gp120_{III8}</u>		A in ELISA
	Without	With	Without	With	with V3 loop
Ab coating*	sCD4	sCD4	sCD4	sCD4	peptidett
3C9+ Ab	5058	1539	8394	1963	0.07
Normal hIg	145	151	282	278	----
V3-specific hAB	----	----	----	----	1.77

15 (polyclonal)

†Plates were coated with 0.3 ug of antibody per well. After addition of PBS containing 10% fetal calf serum to block the absorbed layer, 5 x 10⁴ cpm of ¹²⁵I-labeled gp120_{SF2} or ¹²⁵I-labeled gp120_{III8} was added to each well in the presence or absence of sCD4 at 50 ug/ml. After 3 hr, the plates were washed and the radioactivity was measured.

*3C9+ Ab was purified from HIV⁺ human sera on a 3C9-conjugated Sepharose column, normal human immunoglobulin (hIg) was from The Binding Site (San Diego), and V3-specific human polyclonal antibodies (hAb) were purified from HIV⁺ human sera on a V3_{SF2}-conjugated Affi-Gel column as described (Kang et al. (1991) Proc. Natl. Acad. Sci USA 88, 6171-6175).

††Plates were coated with 0.25 mg of V3_{SF2} peptide in PBS per well. After addition of PBS containing 1% BSA to block the absorbed layer, 1 ug of antibodies per ml of PBS were added to the plates. Alkaline phosphatase-coupled goat anti-human Ig and phosphatase substrate were used to detect antibodies binding to the plates. Absorbance was measured at 405 nm.

SUBSTITUTE SHEET

3C9 mAb Induces Anti-gp120 Ab3 Antibodies

To test whether 3C9 elicit anti-gp120 antibodies, four cynomolgus monkeys were immunized with 3C9 mAb in Syntex adjuvant formulation. Since the immune serum was
5 expected to contain 3C9-specific antibodies (Ab3) and mouse immunoglobulin-specific antibodies (anti-isotype Ab), it was fractionated on successive affinity columns and tested for binding to gp120. Ab3 from two monkeys bound to gp120_{SF2} in an antibody concentration-dependent
10 manner and to gp120_{IIIB} in an antigen concentration-dependent manner, whereas anti-isotype Abs did not bind to either type of gp120. See Fig. 12. Similar results were obtained with Ab3s from two other monkeys (data not shown). Inhibition assays were performed to analyze the
15 specificity of Ab3. The results in Table 4 show that gp120 binding of Ab3 from monkeys PR0703 and PR0783 were inhibited by 3C9 anti-idiotypic mAb (Ab2), human 3C9+Ab (Ab1), sCD4. Similar results were obtained with Ab3s from other monkeys (data not shown). These results confirm the
20 anti-clonotypic nature of 3C9 as it is able to induce in primates gp120-specific Ab3 with similar specificity to the human anti-gp120 antibodies (3C9⁺Ab) purified on 3C9 immunoadsorbent (See Table 3).

Table 4
Inhibition of Ab3 Binding to gp120_{SF2} by Various Inhibitors

5	Monkey Ab3 binding			
	to gp120 _{SF2}	Inhibitor	Conc., ug/ml	%inhibition
10	PRO703 Ab3	3C9	5	94
		3C9 ⁺ Ab*	5	98
		sCD4	30†	73
		BSA	100	2
15	PRO783 Ab3	3C9	5	95
		3C9 ⁺ Ab*	5	97
		sCD4	30†	79
		BSA	100	0

Plates were coated with 2 ug of antibody per well. After addition of PBS containing 10% fetal calf serum to block the adsorbed layer, 1.5×10^5 of ^{125}I -labeled gp120_{SF2} was added to each well in the presence or absence of inhibitors. After 3 hr, the plates were washed, the radioactivity was assayed, and the percent inhibition was calculated.

*3C9⁺ Ab was purified from HIV⁺ human sera on a 3C9-conjugated Sepharose column.

†At this concentration, sCD4 did not inhibit V3 region-specific antibody to gp120_{SF2}, as previously described.

Monkey Ab3 antibodies were further fractionated on a gp120_{SF2}-Sepharose affinity column. The flowthrough and bound fractions were collected as non-gp120-specific Ab3 and gp120-specific Ab3, respectively. These antibodies were then examined for gp120 binding activity. The data in Table 5 shows that all gp120-specific Ab3 from four monkeys bound to gp120, whereas non-gp120-specific Ab3 did

not. This finding indicates that only a fraction of Ab3 recognized gp120 and also suggests that the gp120-specific Ab3 from all four monkeys had a range of affinities for gp120. For example, gp120-specific Ab3 of PRO703 exhibited a 3 to 4-fold higher binding to gp120 than that of gp120-specific Ab3 from the other three monkeys.

Table 5
Binding of gp120-Specific Ab3 Antibodies to gp120

Monkey	Ab3, ug per well	Binding of ^{125}I -labeled gp120 _{SF2} to Ab3, cpm	
		gp120-specific	non-gp120 specific
		Ab3	Ab3
PRO703	1	11,557	218
	0.2	2,324	137
PRO783	2	6,156	402
	0.5	2,803	314
PRO419	1	4,300	236
	0.5	1,477	NT
	0.25	702	NT
PRO431	1	5,738	212
	0.5	2,161	NT
	0.25	1,100	NT

For the binding assays, RIA plates were coated with different amounts of purified anti-gp120 Ab3 for 18 hr with various amounts of antibody in PBS. The plates were blocked with 1% BSA in PBS, and 1×10^5 cpm of ^{125}I -labeled gp120_{SF2} was added to each well. After 3 hr, the plates were washed and the radioactivities were measured. NT, not tested.

Neutralizing Activity of gp120-Specific Ab3

Finally, Applicant examined the HIV-1 virus neutralizing activities of gp120-specific Ab3 antibodies. Table 6 summarizes the results. The gp120-specific Ab3 from PRO703 neutralized MN, IIIB and RF strains of HIV-1. The gp120-specific Ab3 from PRO431 strongly neutralized the RF strain, and weakly neutralized the MN and IIIB strains. The gp120-specific Ab3 from PRO419 and PRO783 neutralized RF and MN, respectively. The lower or limited neutralizing activity of the gp120 specific Ab3s from PRO419, PRO431 and PRO783 may be due to lower affinity against certain gp120s. The gp120 binding activity of gp120-specific Ab3 from these monkeys was considerably lower than that of gp120-specific Ab3 from PRO703 (Table 5).

SUBSTITUTE SHEET

Table 6.

Neutralizing Activity of gp120-Specific Ab3 Antibodies
Isolated From 3C9 Immune Primate Sera

5	Monkey	Ab3, ug/ml	Neutralizing activity as % inhibition of HIV isolates		
			HIV _{MN}	HIV _{IIIB}	HIV _{RF}
	PRO703	30	97	82	84
		10	97	20	94
10	PRO783	55	82	0	ND
		18.8	8	0	ND
	PRO419	30	10	20	96
		15	8	0	98
		7.5	13	9	96
15	PRO431	30	46	67	96
		15	17	56	98
		7.5	24	0	89

gp120-specific Ab3 antibodies produced by monkey PRO703
20 were isolated from a pool of sera obtained after the
second, third, fifth, and sixth immunizations. gp120-
specific Ab3 antibodies from monkey PRO783 were isolated
from a pool of sera obtained after the second, third,
fifth, sixth, and seventh immunizations. Ab3 antibodies
25 from monkeys PRO419 and PRO431 were isolated from a pool
of sera obtained after the fourth and fifth immunizations.
The neutralizing activity was assessed by comparing the
amount of p24 in the well of the test antibody with that
in the control well. All experiments were performed in
30 triplicate. ND, not done.

Collectively, the results from binding and virus
neutralization studies on antibodies isolated from the
sera of 3C9-immunized non-human primates demonstrate that

SUBSTITUTE SHEET

35

3C9 can stimulate clones of primary B cells to produce
br adly neutralizing HIV-1 antibodies.

SUBSTITUTE SHEET

Claims

1. A method of selecting monoclonal anti-idiotypic antibody reagents useful in vaccine formulations for the treatment or prevention of HIV infection, comprising the steps of:
 - (a) preparing human polyclonal anti-gp120 antibodies (Ab1s);
 - (b) generating a first plurality of monoclonal anti-idiotypic antibodies (Ab2s) that immunologically binds with said human polyclonal anti-gp120 antibodies;
 - (c) selecting a second plurality of monoclonal anti-idiotypic antibodies from said first plurality of antibodies, wherein said second plurality of antibodies are characterized by their ability to immunologically bind with anti-gp120 antibodies that neutralize *in vitro* multiple strains of HIV; and
 - (d) selecting a third plurality of monoclonal anti-idiotypic antibodies from said second plurality antibodies, wherein said third plurality antibodies are characterized by their ability to generate an anti-anti-idiotypic antibody (Ab3) response in a primate host, wherein said anti-anti-idiotypic antibody immunologically binds with gp120 and neutralizes *in vitro* multiple strains of HIV.
2. The method of claim 1, wherein said human polyclonal anti-gp120 antibodies are pooled human sera from HIV positive, asymptomatic individuals.
3. The method of claim 2, wherein the said pooled human sera is purified for anti-gp120 antibodies by passing said pooled human sera over a column with gp120 bound to a stationary phase of said column and selecting, by elution, the bound fraction of anti-gp120 antibodies.
4. The method of claim 1, wherein said first plurality of monoclonal anti-idiotypic antibodies are murine.

SUBSTITUTE SHEET

5. The method of claim 1, wherein said anti-gp120 antibodies of step (c) are human.

6. The method of claim 1, wherein said anti-gp120 antibodies of step (c) are human antibodies selected from
5 said human polyclonal antibodies of step (a).

7. The method of claim 6, wherein said anti-gp120 antibodies of step (c) are selected by passing said human polyclonal antibodies of step (a) over a column with an anti-idiotypic antibody from said first plurality of
10 antibodies bound to a stationary phase of said column, eluting bound fraction of anti-gp120 antibodies and selecting from said bound fraction those anti-gp120 antibodies that are capable of neutralizing *in vitro* multiple strains of HIV.

15 8. A monoclonal anti-idiotypic antibody selected according to the method of claim 1.

9. A monoclonal anti-idiotypic antibody that is capable of eliciting a group neutralizing anti-HIV antibody response in humans.

20 10. A hybridoma cell line capable of producing a monoclonal anti-idiotypic antibody that is capable of eliciting a group neutralizing anti-HIV antibody response in humans.

11. A hybridoma cell line deposited with the ATCC,
25 Rockville, MD, under accession No. HB 10701.

12. A monoclonal antibody produced by the cell line of claim 11.

13. A monoclonal antibody which elicits a substantially equivalent immune response in humans as a

monoclonal antibody produced by the hybridoma cell line of claim 10 or 11.

14. A monoclonal antibody which reacts with and competes for binding to the same anti-gp120 antibody as a monoclonal antibody produced by the hybridoma cell line of claim 10 or 11.

15 15. A vaccine formulation comprising, in admixture with a pharmaceutically acceptable carrier, a monoclonal anti-idiotypic antibody that is capable of eliciting a group neutralizing anti-HIV antibody response in humans.

16. A vaccine formulation comprising, in admixture with a pharmaceutically acceptable carrier, an antibody of claim 8 in a dose sufficient to induce an active immune response in humans.

15 17. A vaccine formulation comprising, in admixture with a pharmaceutically acceptable carrier, an antibody of claim 9 in a dose sufficient to induce an active immune response in humans.

20 18. A vaccine formulation comprising, in admixture with a pharmaceutically acceptable carrier, an antibody of claim 12 in a dose sufficient to induce an active immune response in humans.

25 19. A vaccine formulation comprising, in admixture with a pharmaceutically acceptable carrier, an antibody of claim 13 in a dose sufficient to induce an active immune response in humans.

30 20. A vaccine formulation comprising, in admixture with a pharmaceutically acceptable carrier, an antibody of claim 14 in a dose sufficient to induce an active immune response in humans.

1/10




FIG. 1. Isolation of Id+ Anti-gp120 Abs.

2/10




FIG. 1a.




FIG. 1b.

3/10

FIG. 2.







FIG. 3.



SUBSTITUTE SHEET

4/10

*FIG. 5.***SUBSTITUTE SHEET**

5/10

FIG. 6a.




FIG. 6b.





FIG. 6c.



—■— TOTAL ANTI-gp120 Abs
 - - - □ - - - CD4-SITE Abs

FIG. 7a.




FIG. 7b.





FIG. 7c.



—○— V3-REGION Abs
 —■— NON-V3 Abs
 - - - ○ - - - TOTAL ANTI-gp120 Abs

SUBSTITUTE SHEET

6/10

Characterization of the Corresponding AbIs
Against Different Anti-id Mabs

Characteristics of AbIs

Ab2s	Ab1s	Binding to gp120SF2	Binding to gp120IIIB	Virus Neutralization			
				HIVMN	In HIVIIIB	HIVRF	
3C10	3C10 id	+	-	+++	.	.	.
2D9	2D9 id	+	-	+++	.	.	.
1A12	1A12 id	+	-	+/-	.	.	.
1C9	1C9 id	+	-	+	.	.	.
3A6	3A6 id	+	+	+++	+/-	.	.
3C9	3C9 id	+	+	+++	++	+++	+++
4G11	4G11 id	+	+	+++	+/-	.	.
2A12	2A12 id	+	-	+++	.	.	.
2F2	2F2 id	+	+
4E10	4E10 id	+	+	ND	ND	ND	ND
4G5	4G5 id	+	+	+++	+++	+++	+++
5A8	5A8 id	+	+	+++	++	.	.
5E8	5E8 id	+	+	++	++	.	.

*ND: Not done

FIG. 8.

SUBSTITUTE SHEET

Characterization of the Corresponding Ab3s
Against Different Ab2 in Monkeys

7/10

Characteristics of Ab3s				
Ab2s	Ab3s	Binding to gp120	Virus Neutralizations in	
			HIVMN	HIV111B HIVRF
3C9	3C9 Ab3	++ (2/2)*	+	+
4G11	4G11 Ab3	- (0/2)	-	-
4G5	4G5 Ab3	+	-	-
5A8	5A8 Ab3	- (0/2)	-	-

*Number of positive responses from number of immunized monkeys in parenthesis

FIG. 9.

8/10

Neutralizing Activity of Ab3 Isolated From Monkey Sera

Ab3	Conc. of Ab	Neutralizing Activities as % Inhibition in		
		HIVMN	HIV _{111B}	HIVRF
3C9 Ab3*	30 µg/ml	97%	82%	84%
	10 µg/ml	97%	20%	94%

*Purification was done on Ab2 and gp120 affinity column

FIG. 10.




FIG. 11b.




FIG. 11a.

10/10




FIG. 12a.




FIG. 12b.

INTERNATIONAL SEARCH REPORT

PCT/US 92/01749

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 G01N33/569;	G01N33/68;	A61K39/21; C12P21/08
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	G01N ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	CANADIAN JOURNAL OF MICROBIOLOGY vol. 36, no. 11, 1 November 1990, MONTREAL CANADA pages 811 - 816; R.C. KENNEDY ET AL.: 'Concepts of idiotypic-based vaccines for hepatitis b virus and human immunodeficiency virus.' see page 814, column 2, line 49 - page 815, column 2, line 17; figures 1,3	1,4-14
Y	US,A,4 908 203 (G.B. THORTON ET AL.) 13 March 1990 see column 6, line 16 - column 8, line 5 --- -/-	1-20
<p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
23 JUNE 1992	30.06.92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	VAN BOHEMEN C.G. <i>Ch. van Bohemen</i>	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	<p>AIDS RESEARCH AND HUMAN RETROVIRUSES vol. 6, no. 1, 1 January 1990, NEW YORK NY USA page 42; M.S.C. FUNG ET AL.: 'Anti-idiotypic monoclonal antibodies to a neutralizing antibody (bat123) recognizing an immunodominant domain of hiv-1 gp120.' see the whole document</p> <p>---</p>	1-20

US 9201749
SA 58376

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for those particulars which are merely given for the purpose of information. 23/06/92

US-A-4908203 13-03-90 None